Michael P Dube, VP, Chief Accounting Officer at Intellia Therapeutics, sold NTLA on Jul 1, 2026
Data as of Oct 16
▼ SELL$44.3K2,641 shares at $16.78Michael P Dube VP, Chief Accounting OfficerNTLA Intellia Therapeutics, Inc.
- Traded
- Jul 1, 2026
- Disclosed
- Jul 6, 2026
- Filed
- 5 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NTLA since disclosure
−36.0%
after the sale
Similar stocks (XLV) since disclosure
+9.1%
XLV — its sector index fund
Change in closing price from Jul 6, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.